Bullish Outlook on Vigil Neuroscience Inc. Amid Promising Clinical Data and Unique TREM2 Biology Focus

view original post

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on VIGL stock, giving a Buy rating on November 8.

Don’t Miss our Black Friday Offers:

Graig Suvannavejh’s rating is based on the recent developments and potential of Vigil Neuroscience Inc. The company has promising clinical data on the horizon, with its lead asset VGL101 expected to deliver significant results in the first half of 2025, and VG-3927’s complete phase 1 data anticipated in the first quarter of 2025. Despite underperforming recently, the stock is trading at levels close to its cash value, which suggests that the market isn’t fully valuing its pipeline.

Furthermore, Suvannavejh sees Vigil’s focus on TREM2 biology as a unique advantage, especially in light of high unmet medical needs in neurodegenerative diseases. The potential of its innovative approach and the improving prospects for biomarker-based treatments add to the company’s appeal. Given these factors, combined with the current valuation, Suvannavejh maintains a bullish outlook and an Outperform rating on the stock.

In another report released on November 8, Stifel Nicolaus also maintained a Buy rating on the stock with a $11.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Vigil Neuroscience Inc (VIGL) Company Description:

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families.